ERCC2 and urinary bladder carcinoma: To explore the impact of ERCC2 mutations on cisplatin sensitivity in a bladder cancer model, Cas9 and equal amounts of repair templates harboring Mut or WT* were nucleofected in J82, a malignant human urothelial cell line (23).